-
Dr. Rossignol to Present as Part of 2022 GNEM Symposium Speaker Series
Dr. Francis Rossignol of hte NIH National Human Genome Research Institute (NHBRI) will present as part of theGNEM Symposium Speaker Series presented by the Neuromuscular Disease Foundation. His talk, entitled “ManNAc As A Potential Therapy for GNE Myopathy – Advances and Future Directions” will include discussion of NN109. This talk is free of charge and available virtually. More information…
-
Network Renewal RFAs Posted!
The RFAs for the network renewal were published on September 20, 2022. Please find links below. The deadline for grant submissions is November 21, 2022. Please note that there has been a notice of correction published related to the site RFA: https://grants.nih.gov/grants/guide/notice-files/NOT-NS-23-028.html
-
NN106 Cyto-C Clinical Trial Prospective Biomarker Study Results Published
NN106 CYTO-C Prospective biomarker study results have been published in Neurooncology Advances.
-
NN103 (BeatMG) Study Results Cited in NeurologyLive
Results of the NN103 study were cited in NeurologyLive.
-
NN103 Primary Results published in Neurology
The results of the NN103 Beat MG have been posted online at the American Academy of Neurology.
-
Dixie Ecklund named to Society for Clinical Trials Class of 2021 Fellows
Congratulations to Dixie Ecklund, Director of Operations at the NeuroNEXT DCC, for being selected to join the Society for Clinical Trials Class of 2021 Fellows! Ecklund will be recognized as a new inductee at the virtual SCT annual meeting in May.
-
NeuroNEXT Fellow and CTMC Alum highlighted at Wake Forest CTSI
A NeuroNEXT Fellowship can help young neurology faculty develop their careers, as highlighted by Wake Forest University in an article about former NeuroNEXT Fellow and Clinical Trials Methodology Course (CTMC) alumnus Dr. Heidi Munger Clay (see link below).
-
CTMC: 2021 Call for Applications
We are pleased to announce that the NINDS Clinical Trials Methodology Course (CTMC) is accepting applications for the 2021 cohort. The overarching goal of the CTMC is to help investigators develop scientifically rigorous, yet practical clinical trial protocols. Our focus is on investigators who have not previously designed their own prospective, interventional clinical trials. Course: Due to…
-
NeuroNEXT 2020 Annual Meeting
NeuroNEXT Leadership would like to thank everyone for another successful annual meeting! We were able to celebrate several milestones in our virtual format, including:
-
Update: Clinical Trials Methodology Course 2020
A message from the Executive Committee of the Clinical Trials Methodology Course (CTMC): Due to the global COVID-19 (Coronavirus) pandemic and the number of uncertainties that accompany such a health crisis, the Clinical Trials Methodology Course (CTMC) Executive Committee has decided to postpone the Course until next year. The Executive Committee would like to thank…